Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193437 · ClinicalTrials.gov registry record · Phase 2
Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03193437 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 8 participants.
The verdict
NCT03193437, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and effectiveness of selinexor in patients with advanced thymic epithelial tumor progressing after primary chemotherapy. This is a multicenter, open label phase II trial that uses a Simons two stage design. The study population is adults with histologically confirmed, advanced, inoperable TETs who are progressing after treatment with at least one platinum containing chemotherapy regimen. This study is comprised of 2 similar phase II trials, one running in US (25 patients) and one running in EU (25 patients): There are two study arms: Arm A: Thymoma * Stage 1: 15 patients * Stage 2: 10 patients Arm B: Thymic carcinoma * Stage 1: 15 patients * Stage 2: 10 patients
Interventions
- DRUG Open Label Selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-04-03 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03193437
The ClinicalTrials.gov registry entry for NCT03193437 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Open Label Selinexor is the first listed.
NCT03193437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03193437 about?
NCT03193437 is a clinical study titled "Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy". The purpose of this study is to evaluate the safety, tolerability and effectiveness of selinexor in patients with advanced thymic epithelial tumor progressing after primary chemotherapy. This is a multicenter, open label phase II trial that uses a Simons two stage design. The study population is adu...
What is the current status of trial NCT03193437?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2018-04-03. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT03193437?
The interventions under investigation include: Open Label Selinexor (DRUG).
Who is sponsoring clinical trial NCT03193437?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.